Skip to content
Wearables & measurementEvidence review3 min read

Phone and wearable sensor data tracked symptoms of psychiatric illness across 35 studies

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review. · JMIR mental health · 2019 · Original paper ↗

Key takeaway

A systematic review of 35 studies found that data from phone and wearable sensors were associated with symptoms of schizophrenia, bipolar disorder and depression. Most studies covered bipolar disorder, depression and stress, with few on schizophrenia, and the authors say clinical usefulness for supporting therapy is not yet fully assessed.

Study design

Evidence review

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

The EU-funded m-RESIST project is building a therapeutic program for treatment-resistant schizophrenia that uses phone and wearable data to track behavior. The authors reviewed existing studies to see whether sensor data are linked to psychiatric symptoms, to help judge whether behavioral monitoring can support therapy.

Who and how

Systematic review following PRISMA guidelines. The authors searched Scopus, PubMed, Web of Science and the Cochrane Central Register of Controlled Trials for English-language studies published between September 1, 2009, and September 30, 2018. Included studies reported quantitative data from phone use and/or wearable sensors that were associated with clinical outcomes. The abstract does not report effect sizes or study quality ratings.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    35 studies met the criteria. Most examined bipolar disorder, depression, depression symptoms, stress and stress symptoms, while only a few studied people with schizophrenia.
  2. 2
    Sensor data were associated with symptoms of schizophrenia, bipolar disorders and depression.
  3. 3
    How well this works in clinical settings to support therapy has not yet been fully assessed and, the authors say, needs closer scrutiny.

Limits & uncertainty

  1. 1
    Few of the 35 studies addressed schizophrenia, even though that is the condition m-RESIST targets.
  2. 2
    The abstract reports that sensor data were associated with symptoms but gives no effect sizes or measure of how well they predict them.
  3. 3
    Only English-language studies from 2009 to September 2018 were included, so later and non-English work is missing.
  4. 4
    This reading is based on the abstract only.

What to take from it

Patterns in phone and wearable data, such as activity or phone use, appear to move with mental health symptoms, which is why researchers see promise in them. That does not mean a consumer device can diagnose or monitor a psychiatric condition. Mental health decisions belong with a clinician.

Reading your own data

Sleep, steps and daily activity from a wearable are the kind of sensor data these studies drew on. If you track them alongside your mood, look at your own changes over weeks on the same device, and share sustained shifts with a clinician rather than interpreting them alone.

How to read this evidence

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Mobile Therapeutic Attention for Patients with Treatment-Resistant Schizophrenia (m-RESIST) is an EU Horizon 2020-funded project aimed at designing and validating an innovative therapeutic program for treatment-resistant schizophrenia. The program exploits information from mobile phones and wearable sensors for behavioral tracking to support intervention administration.

Objective

To systematically review original studies on sensor-based mHealth apps aimed at uncovering associations between sensor data and symptoms of psychiatric disorders in order to support the m-RESIST approach to assess effectiveness of behavioral monitoring in therapy.

Methods

A systematic review of the English-language literature, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was performed through Scopus, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials databases. Studies published between September 1, 2009, and September 30, 2018, were selected. Boolean search operators with an iterative combination of search terms were applied.

Results

Studies reporting quantitative information on data collected from mobile use and/or wearable sensors, and where that information was associated with clinical outcomes, were included. A total of 35 studies were identified; most of them investigated bipolar disorders, depression, depression symptoms, stress, and symptoms of stress, while only a few studies addressed persons with schizophrenia. The data from sensors were associated with symptoms of schizophrenia, bipolar disorders, and depression.

Conclusions

Although the data from sensors demonstrated an association with the symptoms of schizophrenia, bipolar disorders, and depression, their usability in clinical settings to support therapeutic intervention is not yet fully assessed and needs to be scrutinized more thoroughly.

Sources & attribution

Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review.

Seppälä J, De Vita I, Jämsä T, Miettunen J, Isohanni M, Rubinstein K, Feldman Y, Grasa E, Corripio I, Berdun J, D'Amico E, M-RESIST Group, Bulgheroni M.

JMIR mental health · 2019-02-20

DOI: 10.2196/mental.9819 ↗PubMed · 30785404 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Cohort study

Activity–stroke and heart attack curves differ by accelerometer processing method

Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.

Preventive Medicine

In-depth explainersRead study →
·Validation study/review

Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven

A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.

Forensic Science International

In-depth explainersRead study →
·Overview of reviews

Activity trackers: about 1,800 more steps a day, but small effects on other outcomes

An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.

The Lancet Digital Health

In-depth explainersRead study →
·Validation study/review

Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages

In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.

Sleep

In-depth explainersRead study →
Wearables & measurement →